bioAffinity Technologies (BIAF) Files IPO Registration Statement

bioAffinity Technologies (NASDAQ: BIAF) has filed for a proposed IPO.

The analyst comments: "bioAffinity Technologies, Inc. is a privately held company incorporated in Delaware addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted cancer treatment. Our Company develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. Research and optimization of our platform technologies are conducted in our laboratories at The University of Texas at San Antonio. We are developing our platform technologies so that, in the future, they will be able to detect and monitor diseases of the lung and other cancers and treat many cancers."

WallachBeth Capital will serve as sole underwriter.

You May Also Be Interested In

• SpaceX Shares Indicated To Open At $155
• Super Micro Computer offers $3.75 billion in convertible preferred shares
• Nasdaq Anticipates SpaceX IPO To Open For Trading Shortly - Bloomberg